AKT1 and cancer: Therefore, a deeper understanding of the immunomodulatory effects of PI3K/AKT/mTOR inhibitors may pave the way for their efficient combination with other therapeutic agents, including immune checkpoint blockers, to enhance clinical outcomes for patients with ARID1A‐deficient cancers.